Novo Holdings could earn big on acquisition bid for Synlab
With 17% ownership of the laboratory services provider, Novo Holdings would likely make a pretty penny if an acquisition offer is accepted.
by albert rønning-andersson, translated by daniel pedersen
Novo Holdings invested in 2016 in Synlab, a provider of laboratory diagnostic services, and has since then increased its stake several times. Today, the investment company of the Novo Nordisk Foundation owns 17% of Synlab shares.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Novo Holdings invests in biotech company for third time
For subscribers
Novo Holdings invests in US-based gene-editing company
For subscribers
